Tuesday, November 12

OPENING KEYNOTE AND INTRODUCTION TO IPVC

• The role of respectful partnership in the delivery of global health goals, with particular reference to Scotland and Malawi.
  Heather Cubie

Wednesday, November 13

PLENARY SESSION 1: HPV- The Fundamentals

• HPV replication throughout the life cycle
  Alison McBride (USA)

• HPV from infection to cancer
  Karl Munger (USA)

• HPV signal transduction-a target for anti-virals
  Michelle Ozbun (USA)

PLENARY SESSION 2: Therapeutic cancer vaccines

• General concepts of cancer interception vaccines
  Olivera Finn

• Combination immunotherapy of HPV-induced cancers, including T cell induction by therapeutic vaccines
  Cornelis Melief
• Clinical trials and promising results to date of therapeutic vaccines (together with immunotherapeutic agents) for HPV-related head and neck and cervical cancers
  Katharine Price

Thursday, November 14

PLENARY SESSION 3: Rapid, low-cost HPV cervical screening technologies to meet elimination.

• Overview of current and emerging technologies for low-cost tests to meet elimination goals introducing the concept of WHO prequalification of assays
  Maribel Almonte

• Screening trials with treatment algorithms of care as one aspect of the elimination program in LMIC
  Rakiya Saidu

• Reaching the third target: Treatment for all.
  Hennie Botha

Friday, November 15

PLENARY SESSION 4: Implementation Science

• An overview of principles of implementation science research with an HPV lens
  Maria Fernandez
• Implementation science of cervical cancer prevention strategies in Nigeria
  Juliet Iwelunmor
• Use of implementation science to strengthen cervical cancer prevention in Argentina
  Silvina Arrossi

CLOSING PLENARY

• Vaccine Technology (preventative and therapeutic)
  Ian Frazer
• Will Australia be the first to eliminate cervical cancer?
  Suzanne Garland (Australia)